+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Hepatitis B Virus (HBV) Market: 10-Year Demand Forecast (2016-2025)

  • ID: 3950078
  • Report
  • Region: Global
  • 69 Pages
  • Koncept Analytics
1 of 6
The Key Factors Driving the Growth of the Hepatitis B Market are an Increase in Liver Cancer and Cirrhosis Deaths, Increasing Ageing Population, Increasing Healthcare Expenditure and Urbanization Leading to Better Monitoring and Screening Procedures.

FEATURED COMPANIES

  • Arbutus Pharma
  • Arrowhead Pharmaceuticals
  • Johnson & Johnson
  • MORE

Hepatitis B is a virus that infects the liver. For most adults who suffer from it for a short time, it is called acute hepatitis B. Sometimes the virus causes a long-term infection which is called chronic hepatitis B. Over time, it can damage the liver. Babies and young children infected with the virus are more likely to get chronic hepatitis B. Abdominal pain, fever, dark urine and joint pain are some of the major symptoms of hepatitis B. Having a chronic HBV may lead to serious implications like liver cancer and liver failure.

Keeping the threat in mind, many governments in the European countries and the US have made it mandatory for the people to go through the screening and proper monitoring since hepatitis B takes time to develop and is not easily recognizable. There are some curative therapies available but they are not very efficient. It is expected that many innovative therapies which have shown positive results in trials will occupy the market in the coming years. Many companies have products related to hepatitis B in their pipeline.

The key factors driving the growth of the hepatitis B market are an increase in liver cancer and cirrhosis deaths, increasing ageing population, increasing healthcare expenditure and urbanization leading to better monitoring and screening procedures. Some of the noteworthy trends and developments of this industry are new HBV treatments in development, government initiative and public awareness, collaboration, innovation and research, preference for biomarker based tests. However, the expansion of hepatitis B market is hindered by rigid competition, management challenges, lack of diagnostic facilities and high cost of medical care and legal regulations.

This report provides an in-depth analysis of the global market along with markets of the US and Europe. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The industry comprises large players such as Arrowhead, Arbutus, Gilead and Johnson & Johnson. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Arbutus Pharma
  • Arrowhead Pharmaceuticals
  • Johnson & Johnson
  • MORE

1. Market Overview
1.1 HBV: Introduction
1.2 Causes of Hepatitis B
1.3 Symptoms of Hepatitis B
1.4 Test and Diagnosis of Hepatitis B
1.5 Risk of Hepatitis B
1.6 HBV Blood Tests
1.7 Chronic HBV Disease Phases
1.8 Current HBV Treatments

2. Global HBV Market Analysis
2.1 Global HBV Market
2.1.1 Global HBV Market Forecast by Value

3. Regional Market Analysis
3.1 The US
3.1.1 The US HBV Market Forecast by Value
3.1.2 The US Chronic HBV Patients Forecast by Volume
3.1.3 The US Diagnosed HBV Patients Forecast by Volume
3.1.4 The US Treated HBV Patients Forecast by Volume
3.2 European Union
3.2.1 European Union HBV Market Forecast by Value
3.2.2 European Union Chronic HBV Patients Forecast by Volume
3.2.3 European Union Diagnosed HBV Patients Forecast by Volume
3.2.4 European Union Treated HBV Patients Forecast by Volume
3.3 Japan
3.3.1 Japan HBV Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increase in Liver Cancer and Cirrhosis Deaths due to HBV
4.1.2 Increase in Ageing Population
4.1.3 Increasing Healthcare Expenditure
4.1.4 Urbanization leading to Better Monitoring and Screening Procedures
4.2 Market Trends
4.2.1 HBV Treatments in Development
4.2.2 Government Initiatives and Public Awareness
4.2.3 Collaboration, Innovation and Research
4.2.4 High Demand for Biomarker Based Tests
4.3 Challenges
4.3.1 Rigid Competition
4.3.2 Management Challenges
4.3.3 Lack of Diagnostic Facilities and High cost of Medical Care
4.3.4 Legal Regulations

5. Competitive Landscape
5.1 Global HBV Therapies in Development by Company
5.2 Global HBV Therapies in Development by Mechanism
5.3 Comparison of Anti-Sense Therapies by Company
5.4 Comparison of Core Inhibitors /CpAMs by Company

6. Company Profiles
6.1 Arrowhead Pharmaceuticals
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Arbutus Pharma
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Arbutus Pharma
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Johnson & Johnson
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Charts:

  • CHB Treatment Timeline
  • Global HBV Market Forecast by Value (2016-2025)
  • The US HBV Market Forecast by Value (2016-2025)
  • The US Chronic HBV Patients by Volume (2016-2025)
  • The US Diagnosed HBV Patients Forecast by Volume (2016-2025)
  • The US Treated HBV Patients Forecast by Volume (2016-2025)
  • European Union HBV Market Forecast by Value (2016-2025)
  • European Union Chronic HBV Patients Forecast by Volume (2016-2025)
  • European Union Diagnosed HBV Patients Forecast by Volume (2016-2025)
  • European Union Treated HBV Patients Forecast by Volume (2016-2025)
  • Japan HBV Market Forecast by Value (2016-2025)
  • Global Ageing Population (2006-2015)
  • Global Healthcare Expenditure (2007-2015)
  • Global Urban Population (2007-2015)
  • Arrowhead’s Revenue and Net Income (2011-2015)
  • Arbutus Revenue and Net Income (2011-2015)
  • Gilead’s Revenues Share by Product Sales (2015)
  • Gilead’s Revenues and Net Income (2011-2015)
  • J&J’s Revenues Share by Product Sales (2015)
  • J&J’s Sales and Net Income (2011-2015)

List of Tables:

  • HBV Blood Tests and Indications
  • Chronic HBV Disease Phases
  • Global HBV Therapies in Development by Company
  • Global HBV Therapies in Development by Mechanism
  • Comparison of Anti-Sense Therapies by Company
  • Comparison of Core Inhibitors/CpAMs by Company
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Arbutus Pharma
  • Arrowhead Pharmaceuticals
  • Johnson & Johnson
  • MORE

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. It is transmitted when blood, semen, or another body fluid from a person infected with the HBV enters the body of anyone who is not infected. Abdominal pain, fever, dark urine and joint pain are some of the major symptoms of hepatitis B. Hepatitis B can spread through sexual contact, sharing needles, syringes, and other drug-injection equipment or from mother to baby at birth. Chronic Hepatitis B can lead to serious health issues, like cirrhosis or liver cancer.

The competition in the HBV industry includes the major pharma companies to HBV focused biotech companies having broad pipeline of products undergoing trials. There is not a potential treatment till now for chronic hepatitis B but trials and results have shown that in the coming years this market will grow after the launch of new products and this segment will create a new space in market. Already many companies are conducting research & development and various products are in different phases which may lead to severe competition in the coming future.

As per the report, the demand for HBV market will be driven by increase in liver cancer and cirrhosis deaths, increasing ageing population, increasing healthcare expenditure and urbanization leading to better monitoring and screening procedures. Some of the noteworthy trends and developments of this industry are new HBV treatments in development, government initiative and public awareness, collaboration, innovation and research, preference for biomarker based tests. However, the expansion of hepatitis B market is hindered by rigid competition, management challenges, lack of diagnostic facilities and high cost of medical care and legal regulations.

This report presents an in-depth analysis of the global market along with markets of the US and Europe. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. A thorough analysis has been conducted on key market players covering their business overview, product portfolio, financial overview and business strategies.

Note: Product cover images may vary from those shown
5 of 6
  • Arbutus Pharma
  • Arrowhead Pharmaceuticals
  • Johnson & Johnson
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3950078
Adroll
adroll